Cramer has a speculative play that could be bought: BioSite (BSTE), a medical diagnostics company that you want to be in if the democrats take over after next year. This is one of the smaller diagnostic testing and drug screening companies (plus heart monitoring and bacteria/parasite infection) testing. This actually helps doctors save time and money by determining early what has to be done to save someone. It also has new stroke and acute coronary and kidney tests coming online this year.
BSTE closed down 0.7% at $55.32 today; shares are up 2% at $56.40 after Cramer discussed this. BSTE had a $900 million market cap before Cramer touted this name and he said it has a huge short interest. The 52-week range is $38.08 to $58.18. This was all noted on tonight’s MAD MONEY on CNBC.
Jon C. Ogg
February 23, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.